Atopic Dermatitis: Seven-Market Drug Forecast and Market Analysis

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $14,995	114 Pages	GlobalData	March, 2025	GBDT19969596

Best Price Guarantee
Price	from $14,995
Length	114 Pages
Publisher	GlobalData
Published Date	March, 2025
SKU	GBDT19969596

Atopic Dermatitis: Seven-Market Drug Forecast and Market Analysis

Summary

This report covers the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan). The report provides an overview of the current treatment options, pipeline products in development, as well as current and future R&D trends. Key topics covered include a strategic competitive assessment of current and future drugs, unmet needs, KOL insights, and implications for the Atopic Dermatitis market. The base year of the sales forecast model is 2023, and the forecast period is 2023-2033.

GlobalData estimated that the atopic dermatitis market was $8.5 billion across the 7MM in 2023. By the end of the forecast period in 2033, sales across these markets will reach $22.5 billion, increasing at a compound annual growth rate (CAGR) of 10.2%. This strong growth will be fuelled by driven by the launch of 17 late-stage pipeline agents, increase in treatment options for all age groups and severities, high diagnosed prevalence of atopic dermatitis and high treatment rates across all markets in the 7MM, and novel mechanisms of action anticipated to enter the atopic dermatitis market over the forecast period.

Scope

Overview of AD - including epidemiology, disease etiology and management.
Topline AD drugs market revenue, annual cost of therapy, and anticipated sales for major late-stage pipeline drugs.
Key topics covered include assessment of marketed and pipeline therapies, unmet needs, current and future players and market outlook for the US, 5EU, and Japan over the 10-year forecast period.
Pipeline analysis: Emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
Analysis of the current and future market competition in the global AD therapeutics market. Insightful review of the key industry drivers and barriers.

Reasons to Buy

Develop and design your in-licensing and out-licensing strategies, using a detailed overview of current pipeline products and technologies to identify companies with the most robust pipelines.
Develop business strategies by understanding the trends shaping and driving the seven-market atopic dermatitis (AD) therapeutics market.
Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the seven-market AD market in the future.
Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
Track drug sales in the seven-market AD therapeutics market from 2023-2033.
Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Please note: this is delivered as a Zip file.

1 Atopic Dermatitis: Executive Summary: 1.1 AD market to experience significant growth from 2023-33; 1.2 New players set to enter AD market; 1.3 Opportunities remain for the treatment of AD; 1.4 Novel systemic therapies dominate the late-stage pipeline; 1.5 What do physicians think?
2 Introduction: 2.1 Catalyst; 2.2 Related reports; 2.3 Upcoming reports
3 Disease Overview: 3.1 Etiology and pathophysiology; 3.1.1 Etiology; 3.1.2 Pathophysiology; 3.2 Classification or staging systems
4 Epidemiology: 4.1 Disease background; 4.2 Risk factors and comorbidities; 4.3 Global and historical trends; 4.4 7MM forecast methodology; 4.4.1 Sources; 4.4.2 Forecast assumptions and methods; 4.4.3 Forecast assumption and methods: 12-month diagnosed prevalent cases of AD; 4.4.4 Forecast assumptions and methods: 12-month diagnosed prevalent cases of AD by severity 4.5 Epidemiological Forecast for AD (2023-33); 4.5.1 12-month diagnosed prevalent cases of AD; 4.5.2 Age-specific 12-month diagnosed prevalent cases of AD; 4.5.3 Sex-specific 12-month diagnosed prevalent cases of AD; 4.5.4 12-month diagnosed prevalent cases of AD by severity; 4.6 Discussion; 4.6.1 COVID-19 impact; 4.6.2 Limitations of the analysis; 4.6.3 Strengths of the analysis
5 Disease Management: 5.1 Diagnosis and treatment overview; 5.2 KOL insights on disease management; 5.2.1 Treatment approach
6 Competitive Assessment: 6.1 Overview
7 Unmet Needs and Opportunity Assessment: 7.1 Overview; 7.2 More personalized treatments through improved diagnosis; 7.3 High cost of therapeutics; 7.4 Lack of therapeutic options for CHE; 7.5 Better long-term disease control and management
8 R&D Strategies: 8.1 Overview; 8.1.1 Rise of the JAK inhibitors; 8.1.2 Rise of IL-inhibiting biologics; 8.1.3 Personalized approach for AD; 8.1.4 Promising effects of anti-OX40/OX40L therapies; 8.2 Clinical trials design; 8.2.1 Clinical trial design in AD; 8.2.2 Clinical trial design in CHE; 8.2.3 H2H in AD
9 Pipeline Assessment: 9.1 Overview 9.2 Promising drugs in clinical development; 9.2.1 Mild to moderate AD agents; 9.2.2 Moderate-to-severe agents
10 Pipeline Valuation Analysis: 10.1 Overview; 10.2 Competitive assessment; 10.2.1 Systemic agents; 10.2.2 Topical agents
11 Current and Future Players: 11.1 Overview; 11.2 Deal-making trends
12 Market Outlook: 12.1 Global markets; 12.1.1 Forecast; 12.1.2 Drivers and barriers - global issues; 12.2 US; 12.2.1 Forecast; 12.2.2 Key events; 12.2.3 Drivers and barriers; 12.3 5EU; 12.3.1 Forecast; 12.3.2 Key events; 12.3.3 Drivers and barriers; 12.4 Japan; 12.4.1 Forecast; 12.4.2 Key events; 12.4.3 Drivers and barriers
13 Appendix: 13.1 Bibliography; 13.2 Abbreviations; 13.3 Methodology; 13.3.1 Forecasting methodology; 13.4 Primary research - KOLs and payers interviewed for this report; 13.4.1 KOLs 13.5 Primary research - prescriber survey; 13.6 About the Authors; 13.6.1 Analyst; 13.6.2 Managing Analyst; 13.6.3 Therapy Area Director; 13.6.4 Epidemiologist; 13.6.5 Reviewers; 13.6.6 Vice President of Disease Intelligence and Epidemiology; 13.6.7 Global Head of Pharma Research, Analysis, and Competitive Intelligence
About GlobalData: Contact Us
List of Tables: Table 1: AD: Key metrics in the 7MM; Table 2: Risk factors and comorbidities for AD; Table 3: Treatment guidelines for AD; Table 4: AD approvals across 7MM; Table 5: Top 10 deals by value, 2019-25; Table 6: AD market - global drivers and barriers, 2023-33; Table 7: Key events impacting sales for AD in the US, 2023-33; Table 8: AD market - drivers and barriers in the US, 2023-33; Table 9: Key events impacting sales for AD in the 5EU, 2023-33; Table 10: AD market - drivers and barriers in the 5EU, 2023-33; Table 11: Key events impacting sales for AD in Japan, 2023-33; Table 12: AD market - drivers and barriers in Japan, 2023-33; Table 13: High-prescribing physicians (non-KOLs) surveyed, by country
List of Tables: DNA Oyj, Key Facts; DNA Oyj, Key Employees; DNA Oyj, Key Employee Biographies; DNA Oyj, Major Products and Services; DNA Oyj, History; DNA Oyj, Subsidiaries; DNA Oyj, Key Competitors